• Learn > Schedule of Events

Schedule of Events

Individual presenter disclosures are linked to their names in the Schedule of Events below. You may also view all presenter disclosures at once.

All meeting abstracts are embargoed until Thursday, November 30, at 8:00 a.m. Mountain time. Once the embargo lifts, all abstracts are available on the online conference planner and digital poster viewing is available in the virtual poster library.

Wednesday, November 29, 2023
 
4:00 p.m. - 6:00 p.m. Registration
Thursday, November 30, 2023
7:00 a.m. - 4:30 p.m. Registration
7:00 a.m. - 8:00 a.m. Continental Breakfast and Poster Viewing in the Exhibit Hall
7:50 a.m. - 8:00 a.m. Welcome Address
Vickie Shannon, MD, MD Anderson Cancer Center, Houston [Pulmonologist]
8:00 a.m. - 8:30 a.m. Major Challenges and Opportunities Facing Us in 2023
Moderator: Zhongxing Liao, MD, FASTRO, MD Anderson Cancer Center, Houston [R]
  • What Should be the Treatment if Patients Become Unresectable after Neoadjuvant Immunotherapy?
    • Jessica Donington, MD, MSCR, UChicago Medicine, Chicago [S]
  • Resistance for ICI Immunotherapy: Challenges and Opportunities
    • ​Jianjun Zhang, MD, PhD, MD Anderson Cancer Center, Houston [M]
  • Q&A
8:30 a.m. - 10:00 a.m. The Emerging Benefits of Immunotherapy and Targeted Therapy
Moderator: Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center, New York [M]
  • Stage I SBRT + Immunotherapy
    • Narek Shaverdian, MD, Memorial Sloan Kettering Cancer Center, New York [R]
  • Phase II iSABR Results
    • Joe Chang, MD, PhD, MS, FASTRO, MD Anderson Cancer Center, Houston [R]
  • ADCs and Bispecific mAbs
    • ​Sally Lau, MD, NYU Langone Health, Brooklyn, New York [M]
  • Non-TKI Targeted Therapies (KRAS, G12c, etc.)
    • ​Jia Luo, Dana-Farber Cancer Center, Boston [M]
  • Q&A
10:00 a.m. - 10:30 a.m. Coffee Break and Poster Viewing in the Exhibit Hall
10:30 a.m. - 11:30 a.m. Pearls, Pitfalls and Challenges in Toxicities Associated with Immunotherapy and Targeted Therapies: What We Know Now
Moderator: Vickie Shannon, MD, MD Anderson Cancer Center, Houston [Pulmonologist]
  • Emerging Challenges in Immunotherapy and Targeted Therapy: Combination Therapies, Drug Resistance and Drug Rechallenge, Who? How? When?
    • Abdul Rafeh Naqash, MD, Johns Hopkins University, Baltimore [Professor]
  • Emerging Challenges in Immunotherapy and Targeted Therapy: Lung Toxicity Diagnosis, Risk Factors and Treatment
    • ​Karthik Suresh, MD, Johns Hopkins Medicine, Baltimore [Pulmonologist]
  • Q&A
11:30 a.m. - 12:15 p.m. Modern Substance Use Disorders – ​What's NOT on the Med List?
Moderator: Linda Martin, MD, MPH, University of Virginia Health Systems, Charlottesville, Virginia [S]
  • Nicotine Addiction, and How to Properly Prescribe Tobacco Cessation Meds
    • ​Matthew Steliga, MD, UAMS Health, Little Rock, Arkansas [S]
  • Non-Rx Drugs - the Good, the Bad and the Ugly - Impact on Cancer Treatments
    • Deepti Behl, MD, Sutter Medical Center, Sacramento, California [M]
  • Panel Discussion and Q&A

Early Detection
Moderator: Thomas Stinchcombe, MD, Duke Cancer Center, Durham, North Carolina [M]
  • Screening Criteria and Models: Who is Included and Excluded and How to Apply the Current Models
    • ​Summer Han, Stanford University, Palo Alto, California [Professor]
  • Better Use of CT Scan Images from Novel Diagnostic Techniques
    • Elaine Shum, MD, NYU Langone Health, Brooklyn, New York [M]
  • Blood Based Testing for Screening
    • Aadel Chaudhuri, MD, PhD, Washington University, St. Louis [R]
  • Q&A
12: 15 p.m. - 1:30 p.m. Lunch and Poster Viewing in the Exhibit Hall

Early Career and Trainee Networking Luncheon: Choosing Your Career Path
  • Marina Garassino, MD, University of Chicago Medicine, Chicago [M]
  • Zhongxing Liao, MD, FASTRO, MD Anderson Cancer Center, Houston [R]
  • Thomas Stinchcombe, MD, Duke Cancer Center, Durham, North Carolina [M]
1:30 p.m. - 3:00 p.m. Plenary Abstract Session
Moderator: David Carbone, MD, PhD, The Ohio State University, Columbus, Ohio [M]
3:00 p.m. - 3:30 p.m. Coffee Break and Poster Viewing in the Exhibit Hall
3:30 p.m. - 4:30 p.m. The Changing Landscape of Lung Cancer Biomarkers
Moderator: Kurt Schalper, MD, Yale University, New Haven, Connecticut [Surgical Pathologist]
  • Current and Future Biomarkers for Immunotherapy, Targeted Therapies and ADCs in NSCLC
    • Kurt Schalper, MD, Yale University, New Haven, Connecticut [Surgical Pathologist]
  • Molecular Classification and Novel Biomarkers for Small-Cell Lung Cancer
    • ​Triparna Sen, PhD, Mount Sinai, New York [Professor]
  • Role of Pathologic Response Assessment and Non-Invasive Biomarkers/Liquid Biopsy in Resectable NSCLC
    • Sanja Dacic, MD, PhD, Yale University, New Haven, Connecticut [Pathologist]
  • Role of Digital Pathology and Advanced Computational Analysis/AI in Lung Cancer Management
    • ​Anant Madabhushi, PhD, Emory University, Atlanta [R]
  • Q&A
4:30 p.m. - 5:30 p.m. Networking Reception and Poster Q&A 01 Session in the Exhibit Hall
Friday, December 1, 2023
7:00 a.m. - 5:00 p.m. Registration Open
7:00 a.m. - 8:00 a.m. Continental Breakfast and Poster Viewing in the Exhibit Hall
7:55 a.m. - 8:00 a.m. Welcome Address
Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center, New York [M]
8:00 a.m. - 9:30 a.m. Perioperative and Postoperative Therapies for Resectable Lung Cancer
Moderator: David Carbone, MD, PhD, The Ohio State University, Columbus, Ohio [M]
  • Targeted and Immunotherapies in Surgically Resectable Non-small Cell Lung Cancer
    • Marina Garassino, MD, University of Chicago Medicine, Chicago [M]
  • Impact of Perioperative Therapies on the Surgical Management of Lung Cancer
    • Neel Chudgar, MD, Montefiore Medical Center, New York [S]
  • The Role of Radiation in Surgically Resectable Lung Cancer
    • Jeremy Brownstein, MD, The Ohio State University, Columbus, Ohio [R]
  • Q&A
9:30 a.m. - 10:00 a.m. Coffee Break and Poster Q&A 02 Session in the Exhibit Hall
10:00 a.m. - 10:45 a.m. Impact of Frailty and Other Co-Morbidities on Lung Cancer Outcomes
Moderators: Philip Linden, MD, University Hospitals Cleveland Medical Center, Cleveland [S]
Sue Yom, MD, PhD, FASTRO, UCSF Bakar Precision Medicine Center, San Francisco [R]
  • How to Assess Fitness for Lung Resection
    • Leonidas Tapias, MD, University Hospitals Cleveland Medical Center, Cleveland [S]
  • Comorbidity and Frailty Considerations with Systemic Therapy
    • Mehmet Altan, MD, MD Anderson Cancer Center, Houston [M]
  • Comorbidity and Frailty Considerations with Chemoradiation
    • Pranshu Mohindra, MD, University Hospitals Cleveland Medical Center, Cleveland [R]
  • Q&A
Oligometastatic NSCLC: Current Evidence and Future Directions
Moderator: Kristin Higgins, MD, Emory University, Atlanta [R]
  • Current Data and Clinical Trials that Will Define the Role in RT in Oligometastatic Disease
    • Daniel Gomez, MD, MBA, Memorial Sloan Kettering Cancer Center, New York {R]
  • Potential Biomarkers for Patient Selection in Oligometastatic Space
    • Puneeth Iyengar, MD, University of Texas Southwestern Medical Center, Dallas [R]
  • Discussion and Q&A
10:45 a.m. - 11:45 a.m. Finding and Removing Small Nodules – Keeping Up with Technological Advances
Moderator: Biniam Kidane, MD, MS, University of Manitoba, Winnipeg, Manitoba, Canada [S]
  • The State of Evidence regarding Sublobar Resection for Small Early-Stage Lung Cancer
    • ​Anna McGuire, MD, MSc, FRCSC, Vancouver Coastal Health Research Insitute, Vancouver, British Columbia, Canada [S]
  • Robotic Bronchoscopy and Navigational Bronchoscopy to Find Small Nodules
    • Otis Rickman, DO, Vanderbilt University Medical Center, Nashville, Tennessee [Professor]
  • Molecular Localization of Lung Nodules
    • ​Doraid Jarrar, MD, FACS, FCCP, Penn Medicine, Philadelphia [S]
    Q&A
11:45 a.m. - 1:00 p.m. Lunch and Poster Viewing in the Exhibit Hall

Early Career and Trainee Networking Luncheon: Launching Your Successful Career
  • David Carbone, MD, PhD, The Ohio State University, Columbus, Ohio [M]
  • Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center, New York [M]
1:00 p.m. - 2:15 p.m. Oral Abstract Session
Moderator: Ticiana Leal, MD, Emory University, Atlanta [M]
2:15 p.m. - 2:45 p.m. Coffee Break and Poster Q&A 03 Session in the Exhibit Hall
2:45 p.m. - 4:00 p.m. Review/Update on Thymic Malignancy and Mesothelioma
Moderator: Stephen Chun, MD, MD Anderson Cancer Center, Houston [R]
  • Surgical Considerations in Resectability for Mesothelioma and Thymic Tumors
    • ​Andrea Wolf, MD, Mount Sinai, New York [S]
  • Postoperative Radiotherapy Field Design for Mesothelioma and Thymic Tumors
    • Quynh-Nhu Nguyen, MD, MD Anderson Cancer Center, Houston [R]
  • Systemic Therapy Updates for Mesothelioma and Thymic Tumors
    • ​Matthew Gubens, MD, MS, University of California, San Francisco [M]
  • Q&A
4:00 p.m. - 5:00 p.m. Novel Approaches in Limited Stage and Extensive Stage Small Cell Lung Cancer
Moderator: Percy Lee, MD, FASTRO, City of Hope, Irvine, California [R]
  • Molecular Subclassification and Implications in SCLC Personalized Therapy
    • Jyoti Malhotra, MD, MPH, City of Hope, Irvine, California [M]
  • Novel Advances in Radiotherapy for SCLC
    • Kristin Higgins, MD, Emory University, Atlanta [R]
  • Role of Brain Directed Radiotherapy for SCLC in 2023
    • ​Vinai Gondi, MD, Northwestern Medicine Cancer Center, Warrenville, Illinois [R]
  • Q&A
Saturday, December 2, 2023
7:00 a.m. - 12:00 p.m. Registration Open
7:00 a.m. - 8:00 a.m. Continental Breakfast
7:55 a.m. - 8:00 a.m. Welcome Address
Linda Martin, MD, MPH, University of Virginia Health Systems, Charlottesville, Virginia [S]
8:00 a.m. - 9:30 a.m. Stage III: Innovation on the "Big Stage"
Moderator: Sue Yom, MD, PhD, FASTRO, UCSF Bakar Precision Medicine Center, San Francisco [R]
  • Neoadjuvant Therapy for Resectable Stage III
    • ​Linda Martin, MD, MPH, University of Virginia Health Systems, Charlottesville, Virginia [S]
  • Adjuvant Therapy for Resectable Stage III
    • Salma Jabbour, MD, FASTRO, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey [R]
  • Immunotherapy in Unresectable Stage III
    • Steven Lin, MD, PhD, MD Anderson Cancer Center, Houston [R]
  • Targeted Therapy in Unresectable Stage III
    • ​Carl Gay, MD, PhD, MD Anderson Cancer Center, Houston [M]
  • Q&A
9:30 a.m. - 10:30 a.m. Sexual Health and Fertility Preservation under Psychosocial Oncology
Moderator: Kristin Rojas, MD, FACS, University of Miami Health System, Miami [S]

Speaker: Terri Woodard, MD, MD Anderson Cancer Center, Houston [Professor]
10:30 a.m. - 10:45 a.m. Coffee Break
10:45 a.m. - 11:45 a.m. Difficult Discussions – Prognosis, Therapeutic Choices, End of Life
Moderator: Ticiana Leal, MD, Emory University, Atlanta [M]
  • Discussing Phase I Clinical Trials with Patients with Advanced NSCLC: Challenges and Opportunities
    • ​Jennifer Carlisle, MD, Emory University, Atlanta [M]
  • Tools to Improve Communication between Physicians and Patients
    • Kate Schueller, MD, University of Wisconsin, Madison, Wisconsin [M]
  • Integration of Early Palliative Care to Improve Outcomes in Patients with NSCLC
    • ​Carolyn Presley, MD, The Ohio State University, Columbus, Ohio [M]
  • Financial Toxicity
    • ​Meera Ragavan, MD, Kaiser Permanente, San Francisco [M]
  • Q&A
11:45 a.m. - 12:00 p.m. Symposium Key Takeaways and What's Coming Down the Pipeline
Sue Yom, MD, PhD, FASTRO, UCSF Bakar Precision Medicine Center, San Francisco [R]

CO-SPONSORS

TERMS OF USE & PRIVACY POLICY

 

Connect With Us: